Bionano Reports Q3 Revenue of $8.3 Million

The San Diego genomics company posted a 12% revenue increase and reiterated its full-year 2026 revenue guidance.

Updated on Nov. 10, 2026 in Corporate Finance

Bold flat-color editorial illustration of a single unlabeled flowcell cartridge with parallel microchannels in a matte cradle against a deep navy field.
Bionano Genomics reported third quarter 2026 revenue of $8.3 million, up 12% from a year earlier, and reiterated full-year guidance of $31 to $33 million. AI Illustration. Upload story photo >

Bionano Genomics reported third quarter 2026 total revenue of $8.3 million, up 12% from $7.4 million a year earlier. The company also reiterated full-year 2026 revenue guidance of $31 to $33 million.

Why it matters

The results show growth in flowcell sales and a reduction in operating expenses, indicators investors and customers track in the company's optical genome mapping business. Reiterated guidance gives a benchmark for the company's expected revenue for the year.

Bionano's third quarter 2026 revenue of $8.3 million rose 12% year over year, with flowcell sales up 18% to 9,870 units and gross margin at 48% versus 46% a year earlier. Operating expenses fell 12% to $10.5 million, while the company's full-year 2026 revenue guidance of $31 to $33 million remains unchanged.

The players

Bionano Genomics, Inc.

A San Diego-based genomics company that develops optical genome mapping technology used in clinical and research genetic testing.

The details

Revenue growth was driven by higher flowcell sales and product revenue, while operating expenses declined mainly from lower selling, general and administrative expense. Adjusted operating expense fell 9% to $8.8 million, and the company also announced several OGM-related reimbursement and state-level approval milestones, along with three independent peer-reviewed publications on OGM in myelodysplastic syndromes, acute myeloid leukemia and therapy-related myeloid neoplasms.

Timeline

  1. • September 30, 2026: End of the third quarter results period.

  2. • November 10, 2026: Results release and conference call.

Corporate Finance Trajectory

The quarter's results fit a pattern in which optical genome mapping moves from research use toward clinical reimbursement, with the company citing coverage progress and new peer-reviewed publications as drivers of broader adoption. Management expects these developments to support growth in 2027 and beyond, though the extraction does not quantify that expectation.

Investors tracking Bionano can compare the reiterated $31 to $33 million full-year revenue guidance against the $8.3 million reported for the third quarter when evaluating the company's trajectory. Operating expense reductions and gross margin movements are the figures to watch in future quarterly filings.

The takeaway

For investors, the key metrics to monitor are revenue growth against the reiterated $31 to $33 million guidance and whether operating expense reductions persist. Progress on reimbursement and publications may influence future flowcell demand.

Further reading

Track more company disclosures in the Corporate Finance section.

More information

Visit the Bionano company website for additional corporate information.